Association between Copeptin and Metabolic Syndrome: A Systematic Review
Background: Copeptin, a reliable marker for vasopressin release, has been associated with cardiometabolic diseases including metabolic syndrome (MetS). This systematic review aims to evaluate the association between copeptin and MetS. Methods: We searched in Pubmed, Scopus, EMBASE, and Web of Scienc...
Guardado en:
| Autores principales: | , , , |
|---|---|
| Formato: | Artículo de revisión |
| Lenguaje: | inglés |
| Publicado: |
2022
|
| Acceso en línea: | Ver en el sistema de origen Descargar el archivo Enlace permanente (DOI o Handle) Enlace permanente (DOI o Handle) |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| _version_ | 1881762129006034944 |
|---|---|
| author | Rojas Humpire, Ricardo Josue Soriano‐Moreno, David R. Galindo-Yllu, Brenda Zafra‐Tanaka, Jessica Hanae |
| author_browse | Galindo-Yllu, Brenda Rojas Humpire, Ricardo Josue Soriano‐Moreno, David R. Zafra‐Tanaka, Jessica Hanae |
| author_facet | Rojas Humpire, Ricardo Josue Soriano‐Moreno, David R. Galindo-Yllu, Brenda Zafra‐Tanaka, Jessica Hanae |
| author_sort | Rojas Humpire, Ricardo Josue |
| collection | Producción científica |
| description | Background: Copeptin, a reliable marker for vasopressin release, has been associated with cardiometabolic diseases including metabolic syndrome (MetS). This systematic review aims to evaluate the association between copeptin and MetS. Methods: We searched in Pubmed, Scopus, EMBASE, and Web of Science databases until March 2021 and included observational studies (cohort studies, cross-sectional, and case-control) reporting the risk or prevalence of having MetS in patients with elevated copeptin levels compared to patients without elevated copeptin levels. The risk of bias was evaluated with the Newcastle-Ottawa Scale. Meta-analysis was not performed because of the heterogeneity of the copeptin cut-off values. Results: A total of 7 studies (5 cross-sectional, 1 case-control, and 1 cohort) were included comprising 11,699 participants. Most of them were performed in the adult general population. Two cross-sectional and one case-control studies found a positive significant association between higher levels of copeptin and MetS. While three cross-sectional and one cohort studies found no association. The case-control study had several methodological limitations, most cross-sectional studies were methodologically adequate and the cohort study had no methodological issues. Conclusions: The association between copeptin and MetS is inconsistent. However, the arginine-vasopressin system impairment contributes to metabolic disorders, expressing plasma copeptin changes. Thus, more longitudinal studies are required to corroborate the association of copeptin and MetS. |
| format | Review |
| fuente_str | CRIS |
| fuente_tipo_str_mv | CRIS|Review |
| id | oai:cris.upeu.edu.pe:20.500.15037/552 |
| institution | UPeU |
| language | English |
| publishDate | 2022 |
| publishDateRange | 2022 |
| publishDateSort | 2022 |
| record_format | dspace |
| spelling | oai:cris.upeu.edu.pe:20.500.15037/5522026-11-02T22:00:04ZAssociation between Copeptin and Metabolic Syndrome: A Systematic ReviewRojas Humpire, Ricardo JosueSoriano‐Moreno, David R.Galindo-Yllu, BrendaZafra‐Tanaka, Jessica HanaeBackground: Copeptin, a reliable marker for vasopressin release, has been associated with cardiometabolic diseases including metabolic syndrome (MetS). This systematic review aims to evaluate the association between copeptin and MetS. Methods: We searched in Pubmed, Scopus, EMBASE, and Web of Science databases until March 2021 and included observational studies (cohort studies, cross-sectional, and case-control) reporting the risk or prevalence of having MetS in patients with elevated copeptin levels compared to patients without elevated copeptin levels. The risk of bias was evaluated with the Newcastle-Ottawa Scale. Meta-analysis was not performed because of the heterogeneity of the copeptin cut-off values. Results: A total of 7 studies (5 cross-sectional, 1 case-control, and 1 cohort) were included comprising 11,699 participants. Most of them were performed in the adult general population. Two cross-sectional and one case-control studies found a positive significant association between higher levels of copeptin and MetS. While three cross-sectional and one cohort studies found no association. The case-control study had several methodological limitations, most cross-sectional studies were methodologically adequate and the cohort study had no methodological issues. Conclusions: The association between copeptin and MetS is inconsistent. However, the arginine-vasopressin system impairment contributes to metabolic disorders, expressing plasma copeptin changes. Thus, more longitudinal studies are required to corroborate the association of copeptin and MetS.Reviewhttps://pubmed.ncbi.nlm.nih.gov/36317191https://downloads.hindawi.com/journals/jnme/2022/5237903.pdfhttps://doi.org/10.1155/2022/5237903PMC961769510.1155/2022/5237903https://hdl.handle.net/20.500.15037/55236317191W4307080926enJournal of Nutrition and Metabolism2090-07242090-07322022-10-222026-06-13T08:17:07Z2026-06-13T08:17:07Z |
| spellingShingle | Rojas Humpire, Ricardo Josue Soriano‐Moreno, David R. Galindo-Yllu, Brenda Zafra‐Tanaka, Jessica Hanae Association between Copeptin and Metabolic Syndrome: A Systematic Review |
| title | Association between Copeptin and Metabolic Syndrome: A Systematic Review |
| title_full | Association between Copeptin and Metabolic Syndrome: A Systematic Review |
| title_fullStr | Association between Copeptin and Metabolic Syndrome: A Systematic Review |
| title_full_unstemmed | Association between Copeptin and Metabolic Syndrome: A Systematic Review |
| title_short | Association between Copeptin and Metabolic Syndrome: A Systematic Review |
| title_sort | association between copeptin and metabolic syndrome a systematic review |
| url | https://pubmed.ncbi.nlm.nih.gov/36317191 https://downloads.hindawi.com/journals/jnme/2022/5237903.pdf https://doi.org/10.1155/2022/5237903 https://hdl.handle.net/20.500.15037/552 |
| work_keys_str_mv | AT rojashumpirericardojosue associationbetweencopeptinandmetabolicsyndromeasystematicreview AT sorianomorenodavidr associationbetweencopeptinandmetabolicsyndromeasystematicreview AT galindoyllubrenda associationbetweencopeptinandmetabolicsyndromeasystematicreview AT zafratanakajessicahanae associationbetweencopeptinandmetabolicsyndromeasystematicreview |